Control of ligand-gated ion channel (LGIC) expression is essential for the formation, maintenance and plasticity of synapses. Treatment of mouse myotubes with proteasome inhibitors increased the number of surface nicotinic acetylcholine receptors (AChRs), indicating LGIC expression is regulated by the ubiquitin-proteasome system (UPS). Elevated surface expression resulted from increased AChR delivery to the plasma membrane and not from decreased turnover from the surface. The rise in AChR trafficking was the direct result of increased assembly of subunits in the endoplasmic reticulum (ER). Because proteasome inhibitors also blocked ER-associated degradation (ERAD) of unassembled AChR subunits, the data indicate that the additional AChRs were assembled from subunits normally targeted for ERAD. Our data show that AChR surface expression is regulated by the UPS through ERAD, whose activity determines oligomeric receptor assembly efficiency.
Introduction
Cells respond to extracellular stimuli by regulating the number and/or activity of surface receptors they express. This regulation is particularly important in neurons and skeletal muscle, where the trafficking and targeting of postsynaptic ligandgated ion channels (LGICs) are critical determinants of synaptic efficacy at the neuromuscular junction (NMJ) (reviewed in Sanes and Lichtman, 2001 ) and at central excitatory synapses (Beattie et al, 2000; Man et al, 2000; Wang and Linden, 2000; Malinow and Malenka, 2002) . The molecular controls of LGIC surface expression remain poorly defined but a number of recent studies have implicated ubiquitylation and the ubiquitin-proteasome system (UPS) in the modulation of synaptic strength by regulating the molecular composition at both pre- (Speese et al, 2003; Zhao et al, 2003) and postsynaptic (Burbea et al, 2002; Ehlers, 2003; Zhao et al, 2003) elements.
Ubiquitin is a 76 aa peptide conjugated to proteins by a multistep enzymatic cascade (reviewed in Glickman and Ciechanover, 2002 ) with a known role in regulating surface protein expression. Monoubiquitylation, the attachment of a single ubiquitin, is a signal for plasma membrane receptor endocytosis (reviewed in Bonifacino and Weissman, 1998; Hicke, 2001) . The synthesis of ubiquitin polymers on proteins (polyubiquitylation) directs substrates to 26S proteasomes where they are degraded (UPS; reviewed in Ciechanover and Schwartz, 1998) . Proteasome inhibitors increase expression of several different proteins at the plasma membrane (Staub et al, 1997; Musil et al, 2000; van Kerkhof et al, 2000; Malik et al, 2001; Shenoy et al, 2001; Melman et al, 2002) , but as the UPS influences a wide array of cellular functions, precisely which aspect is critical for surface receptor expression remains unclear.
One well-defined role for the UPS is as part of endoplasmic reticulum-associated degradation (ERAD), which ensures fidelity in the secretory pathway (Brodsky and McCracken, 1999) . As part of this mechanism, the UPS degrades membrane proteins that misfold in the endoplasmic reticulum (ER) like the mutant cystic fibrosis transmembrane regulator (CFTR DF508 ) (Ward et al, 1995) , as well as unassembled subunits of oligomeric receptors (Yu et al, 1997; Tiwari, 2001) . Proteasome inhibitors prevent CFTR DF508 degradation but cannot rescue its maturation (Ward et al, 1995) , owing to its aggregation in the cytosol (Johnston et al, 1998) . Whether UPS inhibition can rescue unassembled subunit maturation (i.e. oligomeric receptor formation) is not known since those studies of unassembled subunit ERAD have only been performed under conditions where assembly cannot occur. Subunit assembly/maturation efficiency in the ER only ranges between 20 and 40% for a variety of oligomeric receptors/ion channels (Merlie and Lindstrom, 1983; Schmidt and Catterall, 1986; Ward and Kopito, 1994) , suggestive of a potentially significant but uncharacterized role for ERAD in oligomeric receptor assembly.
In this study, we describe a novel point of regulation for oligomeric receptor expression by the UPS through ERAD of unassembled subunits. Using the muscle-type nicotinic acetylcholine receptor (AChR), a hetero-oligomeric ion channel assembled in the ER from individual subunits (a, b, g/e, d) and whose biogenesis is well characterized (reviewed in Green and Millar, 1995; Green, 1999; Keller and Taylor, 1999) , we show that ERAD occurs concurrently with receptor assembly, degrading both assembly-competent and misfolded subunits. Consequently, UPS-mediated degradation modulates AChR assembly efficiency and in doing so regulates the number of mature receptors reaching the plasma membrane.
Results
Proteasome inhibitors increase surface AChR expression C 2 C 12 myotubes constitutively expressing AChRs were used to determine the role of the UPS in AChR assembly and expression. Surface AChR expression assayed in myotubes by 125 I-a-bungarotoxin ( 125 I-Bgt) binding ( Figure 1A ) exhibited a marked increase (30-45%) over untreated myotubes following treatment with various proteasome inhibitors. An increase was also observed for AChRs stably expressed in NIH3T3 cells (B23e; Green and Claudio, 1993) treated with lactacystin (LACT) ( Figure 1A ). To test whether treatment with proteasome inhibitors affects AChR internalization as with other surface proteins (van Kerkhof et al, 2000; Shenoy et al, 2001) , the rate of AChR turnover from the plasma membrane was measured ( Figure 1B) , and was unchanged in myotubes treated with LACT (half-life (t 1/2 ) ¼ 18.1 h) compared to untreated myotubes (t 1/2 ¼17.9 h). These halflife values are similar to values reported previously for AChRs expressed in BC3H-1 cells (Hyman and Froehner, 1983) . In contrast, disrupting lysosomal proteases by ammonium chloride (NH 4 Cl) markedly slowed the rate of AChR turnover (t 1/2 ¼ 47.7 h), consistent with previous studies (Devreotes and Fambrough, 1975; Libby et al, 1980) . These data show that surface AChRs are not degraded directly by proteasomes and that the increase in expression is not the result of decreased receptor turnover.
To determine whether increased AChR surface expression in the presence of LACT was due to increased receptor trafficking, we monitored the arrival of AChRs at the cell surface by 125 I-Bgt binding. Prebinding unlabeled Bgt to the surface ensured that 125 I-Bgt only bound to newly inserted AChRs and not those pre-existing at the plasma membrane. As in Figure 1A , the number of AChRs at the cell surface increased after treatment with LACT (32.673.3%; Figure 1C ). Note that increased AChR appearance at the cell surface was not observed until B90 min post-treatment. Since AChR assembly in the ER requires B90-120 min (Merlie and Lindstrom, 1983; Ross et al, 1991; Green and Claudio, 1993) , these data indicate that proteasome-dependent degradation affects AChRs prior to their transport to the plasma membrane.
Proteasome inhibitors increase AChR assembly
The early events in AChR biogenesis were investigated by pulse-chase analysis of myotubes (Figure 2A-C) . To make certain that proteasome inhibitors did not alter AChR subunit synthesis rates, LACT was added immediately after the pulselabeling of subunits, ensuring that the measurements were only post-translational events. The high-affinity interaction between Bgt and AChRs permitted efficient separation of surface receptors from intracellular receptors. Surface AChRBgt complexes were immunoprecipitated by anti-Bgt antibodies and analyzed by SDS-PAGE to assess the arrival of pulse-labeled AChRs to the cell surface (Figure 2A and B) . LACT treatment increased the number of cell surface AChRs, as illustrated by a comparison of the a subunit band intensities for the LACT-treated and untreated myotubes ( Figure 2B ). As in Figure 1C , increased AChR surface expression was not apparent until B90 min and was B40% greater than untreated myotubes by 4 h of treatment with LACT. In repeated trials of this experiment with a 4.5 h LACT treatment, a and b subunit band intensities increased by 37.772.3 and 41.5711.5% ( Figure 2C ), respectively, confirming that LACT increased the number of assembled AChRs delivered to the plasma membrane. Interestingly, the ratio of a:b subunit band intensities was unaffected by LACT (untreated: 2.270.2; LACT: 2.170.2). The 2:1 ratio indicates that the additional surface AChRs containing labeled subunits were assembled with the proper stoichiometry in the presence of LACT ( Figure 2C ).
By masking surface Bgt-binding sites with unlabeled Bgt prior to solubilization, intracellular complexes could be specifically bound with 125 I-Bgt and immunoprecipitated by an a subunit-specific monoclonal antibody (mAb35) to measure intracellular Bgt-binding site formation. In contrast to the increase in surface AChRs detectable only after B90 min ( Figures 1C, 2A and B) , the number of intracellular Bgt-binding sites increased within 30 min of exposure to LACT, reaching B23% over untreated myotubes by 180 min ( Figure 2D ). The overall increase in intracellular Bgt-binding sites was less than that observed for the surface sites. However, this measurement significantly underestimates the actual percent increase with LACT treatment because it includes Bgt-binding sites formed prior to the start of our assay. Because Bgt-binding sites form on the AChR during assembly in the ER (Merlie and Lindstrom, 1983; Green and Wanamaker, 1998) , the relatively rapid effect of LACT suggests that a UPS-mediated degradation event occurs early during AChR biogenesis. This result was confirmed by metabolic labeling of myotubes using the pulse-chase protocol described in Figure 2A . After anti-Bgt immunoprecipitations to isolate surface receptors, intracellular AChRs were affinitypurified using Bgt-Sepharose (Bgt-Seph). Quantification of intracellular a and b subunits bound to Bgt determined 90 min after the labeling revealed increases of 20.573.5 and 22.874.4%, respectively ( Figure 2E ). Again, the ratio of a and b subunit band intensities was B2:1, indicating that labeled subunits were assembled into a 2 bgd complexes by 90 min but remained intracellular. The rapid increases in intracellular Bgt-binding sites as well as in newly assembled AChRs resulting from LACT treatment demonstrate that proteasome activity affects AChR assembly in the ER.
Unassembled AChR subunits are targets for ERAD
How inhibiting proteasome-mediated degradation leads to increased AChR assembly is unclear. It has long been observed that assembly of AChRs is an inefficient process, incorporating only 20-30% of synthesized subunits (Merlie and Lindstrom, 1983; Ross et al, 1991; Green and Claudio, 1993) . Unassembled subunits do not progress beyond the ER (Blount and Merlie, 1988; Claudio et al, 1989; Sumikawa and Miledi, 1989; Gu et al, 1991) and are degraded rapidly (Claudio et al, 1989; Blount and Merlie, 1990) . From the pulse-chase assays in Figure 2 , we estimate that AChRs assemble in C 2 C 12 myotubes with B30% efficiency. The residual AChR subunits (B70%) are presumed to be unassembled or misfolded, two forms that are known to be rapidly degraded from the ER. The similarities shared with unassembled T-cell receptor subunits (e.g. TCRa) suggest that the majority of AChR subunits in myotubes may be targeted for ERAD. If so, then the increase in AChR assembly could be the result of a decrease in subunit degradation.
To explore this possibility, we tested whether the UPS, through ERAD, degrades unassembled AChR subunits. In C 2 C 12 myotubes and B23e cells, AChR subunit assembly and degradation occur concurrently. To study subunit degradation independent of assembly, we generated cell lines stably expressing individual wild-type or HA-tagged subunits. The effect of LACT treatment on subunit degradation was assayed by pulse-chase analysis ( Figure 3 ). Individual subunits were degraded rapidly and with similar but distinct kinetics. Utilizing half-life values (t 1/2 ) as a quantitative measure of degradation ( Figure 3A , CTRL), unassembled a subunits had the slowest rate of degradation, followed by d, e-HA, b-HA and g-HA. Note that these rates are comparable to those observed for Torpedo (Claudio et al, 1989) and mouse a subunits (Blount and Merlie, 1988) . The presence of an HA epitope tag did not alter subunit degradation kinetics as the rates obtained for a-HA and untagged a subunits did not differ significantly (data not shown). Treatment with LACT slowed degradation of all singly expressed AChR subunits ( Figure 3A , LACT), increasing mean t 1/2 values by as much as four-fold.
Integral membrane ERAD substrates can be retrotranslocated from the ER, deglycosylated, and accumulate in the cytoplasm with proteasome inhibition (Wiertz et al, 1996; Yu et al, 1997; Petaja-Repo et al, 2001 ). In the presence of LACT, we were unable to detect deglycosylated a subunit forms that would have indicated exposure of the N-terminal glycosylation site (N143) to cytosolic N-glycanase ( Figure 3A ). The increased t 1/2 values measured during LACT treatment represent an extended presence of subunits with appropriate molecular weights and glycosylation profiles. Furthermore, all subunits remained associated with membrane fractions upon cellular fractionation (data not shown). These results indicate that proteasomes degrade unassembled AChR subunits from the ER and imply that subunit retrotranslocation is a process coupled tightly to proteasome activity.
Polyubiquitylation targets ERAD substrates to 26S proteasomes for degradation. To assess subunit polyubiquitylation, individual subunits were immunoprecipitated from stably expressing cells treated with proteasome inhibitors, and immunoblotted with anti-ubiquitin (anti-Ub) ( Figure 3C ). Polyubiquitylated proteins appear as high-molecular-weight smears of ubiquitin immunoreactivity. Only after treating with proteasome inhibitors were polyubiquitylated a subunits readily apparent (compare lanes 1 and 2, data not shown). Comparable results were observed for all other AChR subunits ( Figure 3D ). The lysomotropic agents, NH 4 Cl and chloroquine, which blocked surface turnover ( Figure 1B) , had no effect on subunit polyubiquitylation (data not shown), and denaturation with 1% SDS did not disrupt a subunit polyubiquitylation, confirming a covalent modification ( Figure 3C, lane 3) .
AChR subunit ubiquitylation was also assayed in C 2 C 12 myotubes ( Figure 3E ). After solubilization, assembled subunits were removed by affinity purification with Bgt-Seph ( Figure 3E, lanes 1 and 2) . Residual and presumably unassembled subunits were denatured prior to immunoprecipitation ( Figure 3E , a: lanes 4 and 5, b: lanes 6 and 7, d: lanes 8 and 9). As with individually expressed subunits ( Figure 3C and D), polyubiquitylated forms of unassembled a, b and d were detected in myotubes following LACT treatment, indicating that subunit degradation through the UPS is occurring during receptor assembly.
Assembly-competent subunits are targeted for ERAD
To test whether proteasome inhibition permitted the maturation of misfolded subunits, we evaluated biochemical and pharmacological properties of AChRs assembled in the presence of LACT. We began by measuring the dissociation rate of 125 I-Bgt bound to surface AChRs. The toxin dissociation kinetics ( Figure 4A ) for receptors assembled while myotubes were treated with LACT did not differ significantly from untreated myotubes, with estimated t 1/2 values of 8.4 days (CTRL) and 9.2 days (LACT). We next tested whether AChRs expressed during treatment with LACT or NLVS sediment similarly on sucrose gradients ( Figure 4B ). Conformationally mature AChRs are released from the ER as a 2 bgd pentamers and sediment at a 9S peak on sucrose velocity gradients after solubilization in Triton X-100 (Merlie and Lindstrom, 1983) . AChR pentamers not comprised of the full subunit complement dissociate in Triton X-100, as do partially assembled AChR complexes (Green and Claudio, 1993) . Surface AChRs from untreated and LACT (or NLVS)-treated myotubes migrated in a single peak at 9S and their sedimentation was indistinguishable ( Figure 4B ). These results together with our finding of a 2:1 ratio of a:b subunits for surface and intracellular AChRs ( Figure 2C and E) indicate that AChRs assembled in the presence of proteasome inhibitors have the expected size and subunit stoichiometry.
Each AChR has two agonist-binding sites to which ACh binds cooperatively to activate the receptor. Bgt binds to AChRs at locations that overlap with the agonist-binding sites and both sites form during AChR assembly (Green and Wanamaker, 1998) . As a test of ligand-binding site fidelity, we measured the affinities of the competitive antagonist d-tubocurare (dTC; Figure 4C ) and the agonist carbamylcholine (carb; Figure 4D ) by competition with the competitive antagonist 125 I-Bgt. dTC normally binds to the two agonistbinding sites with a 50-to 100-fold difference in affinity (Sine, 1993; Steinbach and Chen, 1995) while the binding of agonists such as carb is cooperative if receptor activation occurs. Both dTC and carb were able to block 125 I-Bgt binding to AChRs and the dose dependence of that block was comparable, indicating that the affinities of dTC and carb were the same for untreated and LACT-treated receptors. Importantly, the shape of each dose dependence curve for either antagonist or agonist was indistinguishable between LACT-treated and untreated cells. A Hill slope of 0.5 was obtained from fitting the Hill equation to the dTC data in Figure 4C consistent with a 50-fold difference in dTC affinity between the two agonist-binding sites. In contrast, a Hill slope of 1.5 was obtained from the fit of the Hill equation to carb data in Figure 4D , indicating cooperative agonist binding and receptor activation. From these results, the loss of proteasome activity did not appear to affect adversely the fidelity of AChR assembly and indicate that receptors formed were comprised of correctly folded and post-translationally modified subunits.
Discussion
Based on the results described in this paper, we propose that the UPS regulates AChR expression through its role in ERAD. Proteasome inhibitors can prevent internalization of some surface receptors including b2-AR (Shenoy et al, 2001) , GHR (van Kerkhof et al, 2000) and IL-2 (Yu and Malek, 2001) , while the turnover of others, such as transferrin receptors (van Kerkhof et al, 2000) , is unaffected. Like the AChR, internalization and degradation of a glycine receptor (GlyR1) in the same LGIC family did not require proteasome I-Bgt using the technique described in Figure 2C and separated on 5-20% sucrose gradients. The quantity of bound 125 I-Bgt in each fraction (total 18) was normalized to the peak fraction (11). Surface AChRs expressed in both LACT-(K) and NLVS-(.) treated myotubes sedimented identically to CTRL (J) at a 9S peak (fractions 10-12) but had 26% (LACT) and 23% (NLVS) more 125 I-Bgt binding than CTRL. After incubation with LACT, the ligands (C) dTC and (D) carb were competed against the initial rate of 10 nM 125 I-Bgt binding. Graphs are plotted as mean and s.e.m. values (n ¼ 3). IC 50 values and Hill coefficients were calculated from curve fits using a three-parameter Hill equation.
activity (Bèuttner et al, 2001) , suggesting that LGIC expression is not regulated by a UPS-dependent mechanism at the plasma membrane.
Ubiquitylation in the Golgi was suggested as a checkpoint for AChR subunit trafficking (Keller et al, 2001 ), but our data do not support a role for the UPS at this level. At least 90 min were required until the effects of LACT could be detected on the cell surface ( Figures 1C and 2B) . AChR assembly requires 90-120 min to complete after subunit synthesis (Merlie and Lindstrom, 1983; Ross et al, 1991) . If proteasomal degradation regulated trafficking after ER release to the Golgi, we would have expected increased AChR expression to be detectable much earlier, since mature AChRs are trafficked to the surface after release from the ER much more rapidly than the time it takes for them to be assembled (Ross et al, 1991) . LACT increased the number of newly assembled AChR complexes ( Figure 2E ) and also the formation of intracellular Bgtbinding AChRs, a process that occurs during AChR assembly in the ER (Green and Wanamaker, 1998) . Little to no lag time was required for LACT to increase Bgt site formation ( Figure 2D ), arguing strongly that UPS regulation occurs at the ER by altering an early aspect of AChR assembly.
Previous studies have shown that there is rapid degradation of unassembled AChR subunits from the ER (Claudio et al, 1989; Blount and Merlie, 1990 ), but the mechanism had not been identified. Because proteasome inhibitors extended the lifetimes of unassembled AChR subunits by as much as four-fold (Figure 3) , ERAD is at least partially responsible for subunit clearance. Unassembled AChR subunit lifetimes in the ER are shorter (30-77 min) than the residence time of subunits that are assembled and released from the ER (90-120 min). This finding suggests that unassembled subunits are not significantly retained in the ER, but rather are continuously removed through ERAD. We estimated that B70% of synthesized a subunits in myotubes are degraded, suggestive of a robust role for ERAD concurrent with receptor assembly. Many large membrane receptors/oligomers share the features of inefficient assembly in the ER and rapid degradation of their constituent subunits including GABA A receptors (Gorrie et al, 1997) , voltage-gated Na þ channels (Schmidt and Catterall, 1986) , CFTR (Cheng et al, 1990; Jensen et al, 1995 ), connexin32 (VanSlyke et al, 2000 and ENaC (Valentijn et al, 1998) . Given these common features, it is likely that ERAD is a general mechanism responsible for continuously clearing unassembled subunits from the ER during oligomeric receptor/ion channel assembly. In Figure 5 , we propose a model for regulation of AChR assembly in the ER by the UPS that may serve as a model for other ion channels/oligomeric receptors. Following cotranslational insertion into the ER membrane ( Figure 5A ), a fraction of unassembled subunits interacts with complementary subunits and chaperones (stabilizing factors) that facilitate folding/oligomerization into mature AChR pentamers competent to exit the ER. Concurrently, subunits that misfold or fail to engage a stabilizing factor are targeted for ERAD. Commitment to ERAD comes as the subunit is polyubiquitylated while still integrated in the ER membrane. Polyubiquitylated subunits are then retrotranslocated (perhaps via lateral gating of Sec61 translocons; Plemper et al, 1998) with the help of cytoplasmic proteasomes, which ultimately degrade them. As implied by the model in Figure 5A , subunit assembly and degradation are processes occurring simultaneously in the ER. It is their opposing activities that ultimately determine the net efficiency at which surface receptors can be expressed.
Proteasome inhibitors caused unassembled subunits to accumulate, resulting in increased AChR assembly efficiency. A model for the causal relationship between these two observations is depicted in Figure 5B . If proteasome activity provided the energy for subunit retrotranslocation as shown in Figure 5A , then inhibiting it could directly affect unassembled subunits levels in the ER membrane. An increase in subunit concentration in the ER favors increased formation of assembly intermediates and consequently AChRs, provided the capacity for oligomerization is retained. Proteasome inhibition causes a number of secreted and single-pass membranes to accumulate cytoplasmically (Wiertz et al, 1996; Yu et al, 1997; de Virgilio et al, 1998; Yang et al, 1998; Shamu et al, 1999) , indicating that retrotranslocation occurred even without proteasome activity. Interactions of the substrate polypeptide and polyubiquitin tree with the AAA-ATPase p97/VCP (and its adaptor complex) are thought to be sufficient to cause these substrates' retrotranslocation (Rabinovich, 2001; Ye et al, 2003) . In contrast, AChR subunits and other proteins appear to require proteasome activity for retrotranslocation (Plemper et al, 1998; Xiong et al, 1999) and p97/VCP activity alone is not sufficient to compensate for this loss. This stark difference suggests that the general mechanism of ERAD also has substrate-specific functional requirements.
Our data demonstrate that a fraction of subunits accumulating in the ER during proteasome inhibition are capable of assembling into mature, functional AChRs. Akin to these findings, increased gap junction formation in 'assemblyinefficient' cells was proposed to result from a net increase in connexins available for assembly after proteasome inhibition . In contrast, proteasome inhibitors fail to rescue surface expression of membrane proteins with mutations that prevent folding in the ER, such as CFTR DF508 (Jensen et al, 1995; Ward et al, 1995) . CFTR DF508 does not fold properly at 371C (Denning et al, 1992) and does not remain integrated in the ER membrane, ultimately precluding its maturation. Only because proteasome inhibitors did not adversely affect the integrity of additional AChRs assembled, can we suggest that the constituent subunits possessed the capacity for maturation. Had proteasome inhibitors not been present, subunits would have been targeted to ERAD as if they were terminally misfolded. Our data strongly suggest that the stringency of the ERAD selection process is low, failing to distinguish between subunits capable of assembling and those terminally misfolded. In this broader view, ERAD functions not just in ER quality control but also in the active governing of assembly efficiency and in turn the level of surface receptor expression.
Given their complex structure, it is not clear how AChR subunits are recognized for ERAD. Identification could stem from aberrant trimming of AChR subunit glycans, which would divert subunits to ERAD through interaction with EDEM (Molinari et al, 2003; Oda et al, 2003) . Alternatively, subunits may transiently expose a degradation signal/motif or 'degron' during tertiary rearrangement. A degron is indicated in the model by the '*' symbol on the unassembled subunits ( Figure 5A ). Degrons have been described as either linear (i.e. cl1 (Gilon et al, 2000) , PEST (Rechsteiner and Rogers, 1996) ) or distributed (Gardner and Hampton, 1999) motifs. For polytopic AChR subunits, a degron could reside in a TM domain (Bonifacino et al, 1991; Wang et al, 2002) , or within a partially folded cytoplasmic loop region accessible by ER resident/cytoplasmic ubiquitylation machinery capable of catalyzing subunit polyubiquitylation (as in Figure 5 ). Polyubiquitylation would preclude subsequent folding/oligomerization steps and divert the subunit to ERAD, perhaps because of engagement with VCP/p97 or 26S proteasomes or by sterically hindering oligomerization. As shown in Figure 5A , oligomerization may obscure each subunit's degron within the assembly intermediate and mature pentameric forms, akin to stabilization of yeast mating factor MATa2 by MATa1 (Johnson et al, 1998) . Consistent with this idea, tandem expression of AChR a and d dramatically increases subunit half-lives compared to expression of each subunit alone (Keller et al, 1998) .
The capacity to modulate ion channel/receptor expression at the level of the ER has important consequences for synaptic plasticity and perhaps in the treatment of some pathological conditions. Synaptic plasticity is regulated by an increasing number of pre-and post-translational mechanisms, and modulation of ERAD may be one more to consider. Organelles of the secretory pathway including ER, ER exit sites and Golgi were identified in neuronal dendrites (Horton and Ehlers, 2003) . With this apparatus in place at synapses, rapid modulation of LGIC assembly/expression through ERAD represents a potential point for post-translational regulation of synaptic strength. And while rapid modulation may not be as prominent at mature NMJs, where AChRs are relatively stable (t 1/2 B10 days), it may play a key role in dynamic synapses such as the developing NMJ or central excitatory/inhibitory synapses. Finally, note that ERAD is also a potential target for therapeutic intervention in diseases characterized by poor LGIC expression (e.g. myasthenia gravis). Current treatments for MG rely on inhibitors of AChesterase, which increase synaptic ACh concentration and enhance activity from residual AChRs left at the NMJ (Lindstrom, 2000) . Increasing the efficiency of AChR assembly/expression through small molecule intervention of ERAD, in conjunction with existing treatment, could potentially improve motor function.
Materials and methods

AChR subunit cDNAs
Mouse AChR subunit cDNAs (a and d) have been reported previously (Eertmoed et al, 1998) . Mouse b, g and e subunit cDNAs were amended with C-terminal hemagglutinin epitope tags (b-HA, g-HA, e-HA) using standard PCR techniques and cloned into pRBG4.
Cell culture and AChR expression tsA201 cells were maintained in DME (Gibco) þ 10% calf serum (CS). Clonal tsA201 lines stably expressing AChR subunits were selected by survival in hygromycin and by immunoreactivity to subunit-specific antibodies. B23e cells are described previously (Green and Claudio, 1993) . C 2 C 12 myoblasts (ATCC) were Figure 5 Model for UPS regulation of AChR assembly. (A) Model of the ER illustrating the concurrent processes of assembly (top) and ERAD (bottom) of unassembled AChR subunits. Normally, only between 20 and 40% of subunits assemble into AChRs, while those remaining are retrotranslocated and degraded rapidly by the UPS. Masking or presentation of a putative 'degron' (indicated by *) on each subunit during folding/oligomerization in the ER determines an assembly or degradation fate, respectively. (B) Loss of proteasome activity results in a decrease of unassembled subunit ERAD and an increase in AChR formation. As subunit retrotranslocation requires proteasome activity, subunits remain integrated in the ER with some retaining the potential for oligomerization into AChRs. maintained in DME þ 10% fetal bovine serum (FBS) until they were B90% confluent. Cells were then switched to DME þ 10% heatinactivated horse serum (HIHS) for 36-48 h followed by starvation for 18 h with DME þ 2.5% HIHS to induce myotube formation and upregulate AChR expression.
Metabolic labeling and pulse-chase assays
Confluent plates of tsA201 stable cell lines were incubated in Met/ Cys-free DME for 10 min. Cells were pulse-labeled by supplementing Met/Cys-free DME with 35 S-Met/Cys (NEN EXPRE 35 S 35 S: 0.33 mCi/ 10 cm plate) for 10 min. Rinsing cells twice with ice-cold phosphatebuffered saline (PBS) supplemented with 5 mM Met terminated labeling. Labeled cells were gently harvested and pelleted at 1000 r.p.m. for 10 s. Following resuspension and washing in DME þ 10% CS supplemented with 5 mM Met, cells were pelleted and resuspended in DME þ 10% CS þ 50 mM HEPES þ 5 mM Met. Suspended cells were divided into five equal volumes and chased in suspension while rotating at 371C. C 2 C 12 myotubes were labeled similarly but were instead starved for 15 min, labeled for 15 min, and the chase carried out on the plates. For AChR subunit synthesis assays, cells were Met/Cys starved and pulse-labeled for 10 min at each time point.
Inhibitors of protein degradation
The following proteasome inhibitors were used: LACT (10 mM, Kamiya Biochem.), NLVS (10 mM, Calbiochem), MG-115 (10 mM, Calbiochem) and MG-132 (1 mM, Alexis). Inhibitors were added to unassembled subunit pulse-chase assays 5 min into the Met/Cys starvation and also included during the labeling and chase periods. For myotubes pulse-chase assays, inhibitors were included only during the chase, but not the 0 h time point. For 125 I-Bgt binding experiments, inhibitors were present continuously. The lysomotropic agents NH 4 Cl (40 mM) and chloroquine (25 mM, Sigma) were added in similar fashion.
I-Bgt (NEN) overnight at 41C, washing three times in PBS and measuring bound radioactivity. Competition assays were performed by preincubating cells with carb or dTC solutions for 15 min, subsequently supplemented with solutions þ 5 nM 125 I-Bgt for 30 min. For surface AChR turnover experiments, myotubes were bound with 10 nM 125 I-Bgt in DME (710 mM LACT) for 1.5 h at 371C, washed three times in PBS to remove excess toxin and chased at 371C. At specified times, media were collected and replaced. Collected samples along with harvested cells were counted, summed and turnover expressed as a fraction of 125 I-Bgt counts remaining (Devreotes and Fambrough, 1975) . Toxin dissociation rates were measured by binding 125 I-Bgt in a similar fashion but cells were instead incubated at 41C in PBS.
Sucrose gradients C 2 C 12 myotubes were bound with 62.5 nM cold Bgt for 1.5 h at 371C, washed three times in PBS, then treated with 10 mM LACT (or NLVS) and 10 nM 125 I-Bgt for 4.5 h at 371C. Cells were washed in PBS, harvested and lysed in 1% TX-100 lysis buffer. TX-100-soluble fractions were layered on 5-20% sucrose gradients prepared in 1% TX-100 lysis buffer. Gradients were centrifuged at 40 000 r.p.m. 
